Lifecore Set To Go Private Under $239 Million Warburg Pincus Buyout Deal
This article was originally published in The Gray Sheet
Executive Summary
Dental implant maker Lifecore Biomedical is on-track to be acquired by private equity firm Warburg Pincus for $239 million after failing to receive a superior proposal, the firm said Feb. 14
You may also be interested in...
Lifecore Biomedical
Supplier of hyaluronic acid biomaterials for medical applications is acquired by diversified materials science firm Landec Corporation for $40 million up-front, plus assumed debt of $4 million and up to $10 million in future milestone payments. Lifecore Biomedical went private in a 2008 buyout deal with private equity firm Warburg Pincus; Lifecore's dental unit then merged with Warburg Pincus portfolio firm Keystone Dental (1"The Gray Sheet" Feb. 18, 2008)
Lifecore Biomedical
Supplier of hyaluronic acid biomaterials for medical applications is acquired by diversified materials science firm Landec Corporation for $40 million up-front, plus assumed debt of $4 million and up to $10 million in future milestone payments. Lifecore Biomedical went private in a 2008 buyout deal with private equity firm Warburg Pincus; Lifecore's dental unit then merged with Warburg Pincus portfolio firm Keystone Dental (1"The Gray Sheet" Feb. 18, 2008)
Acquisitions In Brief
ConvaTec poised to combine with Unomedical: Ostomy and wound care device business ConvaTec, which is being acquired by private equity firms Nordic Capital Fund VII and Avista Capital Partners from Bristol-Myers Squibb under a May 2 deal, will be combined with Danish single-use medical device maker Unomedical, currently owned by Nordic Capital Fund IV, after the ConvaTec deal closes in the third quarter, the investor groups announce June 27. The combination will enable Unomedical to benefit from Skillman, N.J.-based ConvaTec's "global presence and size," and will continue to be known as ConvaTec, the firms state. ConvaTec has annual sales of $1.15 billion, while Unomedical has revenues of about $418 million, based on current exchange rates. Bristol is sharpening its pharma focus (1"The Gray Sheet" May 5, 2008, In Brief)